Cargando…

Preferential binding to dopamine D(3) over D(2) receptors by cariprazine in patients with schizophrenia using PET with the D(3)/D(2) receptor ligand [(11)C]-(+)-PHNO

RATIONALE: Second-generation antipsychotics occupy dopamine D(2) receptors and act as antagonists or partial agonists at these receptors. While these drugs alleviate positive symptoms in patients with schizophrenia, they are less effective for treating cognitive deficits and negative symptoms. Dopam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Girgis, Ragy R., Slifstein, Mark, D’Souza, Deepak, Lee, Yih, Periclou, Antonia, Ghahramani, Parviz, Laszlovszky, István, Durgam, Suresh, Adham, Nika, Nabulsi, Nabeel, Huang, Yiyun, Carson, Richard E., Kiss, Béla, Kapás, Margit, Abi-Dargham, Anissa, Rakhit, Ashok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035321/ https://www.ncbi.nlm.nih.gov/pubmed/27525990 http://dx.doi.org/10.1007/s00213-016-4382-y

Ejemplares similares

Population Pharmacokinetics of Cariprazine and its Major Metabolites
por: Periclou, Antonia, et al.
Publicado: (2020)

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania
por: Periclou, Antonia, et al.
Publicado: (2019)

Cariprazine exerts antimanic properties and interferes with dopamine D(2) receptor β-arrestin interactions
por: Gao, Yonglin, et al.
Publicado: (2015)

Cariprazine Exhibits Anxiolytic and Dopamine D(3) Receptor-Dependent Antidepressant Effects in the Chronic Stress Model
por: Duric, Vanja, et al.
Publicado: (2017)

Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”
por: Periclou, Antonia, et al.
Publicado: (2019)

Binding kinetics of cariprazine and aripiprazole at the dopamine D(3) receptor
por: Frank, Annika, et al.
Publicado: (2018)

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial
por: Durgam, Suresh, et al.
Publicado: (2016)

The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
por: Delcourte, Sarah, et al.
Publicado: (2018)

PET imaging of dopamine-D2 receptor internalization in schizophrenia
por: Weinstein, Jodi J., et al.
Publicado: (2017)

Evaluation of dopamine D(3) receptor occupancy by blonanserin using [(11)C]-(+)-PHNO in schizophrenia patients
por: Sakayori, Takeshi, et al.
Publicado: (2020)

Dopamine D(1) receptors in cocaine dependence measured with PET and the choice to self-administer cocaine
por: Martinez, Diana, et al.
Publicado: (2009)

Exploring regulation and function of dopamine D3 receptors in alcohol use disorder. A PET [(11)C]-(+)-PHNO study
por: Chukwueke, Chidera C., et al.
Publicado: (2021)

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
por: Durgam, Suresh, et al.
Publicado: (2017)

Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine
por: De Pieri, Marco, et al.
Publicado: (2023)

Effect of scan-time shortening on the (11)C-PHNO binding potential to dopamine D(3) receptor in humans and test–retest reliability
por: Matsunaga, Keiko, et al.
Publicado: (2023)

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Fava, Maurizio, et al.
Publicado: (2018)

Comparison of Dopamine D(3) and D(2) Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [(11)C]-(+)-PHNO
por: Tateno, Amane, et al.
Publicado: (2018)

Defining the therapeutic reference range for cariprazine
por: Kapás, M., et al.
Publicado: (2023)

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
por: Nasrallah, Henry A., et al.
Publicado: (2017)

Cariprazine, A Dopamine D(2)/D(3) Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer
por: Hussein, Noor, et al.
Publicado: (2018)

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)
por: Nakamura, Tadakatsu, et al.
Publicado: (2016)

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D(3) Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders
por: Kehr, Jan, et al.
Publicado: (2022)

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
por: Earley, Willie, et al.
Publicado: (2017)

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study
por: Durgam, Suresh, et al.
Publicado: (2016)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D(3) Receptors in the Brain in vivo
por: Kiss, Béla, et al.
Publicado: (2022)

43.4 THE ROLE OF MOLECULAR IMAGING IN GUIDING DRUG DEVELOPMENT
por: Abi-Dargham, Anissa, et al.
Publicado: (2018)

The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices
por: Meier, Maria A., et al.
Publicado: (2020)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020)

PM476. d-Amphetamine-induced sensitization of the dopaminergic system in healthy human subjects: A [(11)C]-(+)-PHNO-PET study
por: Ana, Popovic, et al.
Publicado: (2016)

Association of dopamine D(2/3) receptor binding potential measured using PET and [(11)C]-(+)-PHNO with post-mortem DRD(2/3) gene expression in the human brain
por: Komorowski, Arkadiusz, et al.
Publicado: (2020)

Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders
por: Kiss, Béla, et al.
Publicado: (2021)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Batinic, Borjanka, et al.
Publicado: (2021)

Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder
por: Román, Viktor, et al.
Publicado: (2021)

The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task
por: Barnes, Samuel A., et al.
Publicado: (2018)

Striatal Dopamine Release in Schizophrenia Comorbid with Substance Dependence
por: Thompson, Judy L., et al.
Publicado: (2012)

Correction to: The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task
por: Barnes, Samuel A., et al.
Publicado: (2018)

Vitamin D, vitamin D receptor and tissue barriers
por: Zhang, Yong-guo, et al.
Publicado: (2013)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6kqdhk4ab16eu6b0k9pfrcun23